Biotech Startups

Celerion provides clinical pharmacology and bioanalytical services to support pharmaceutical and biotechnology companies in early-phase drug development and regulatory submissions. The company operates clinical research units and bioanalytical laboratories across North America and Europe.

2 investors

Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots. Its FDA-cleared products are based on the BASHIR Endovascular Catheter platform for medical practitioners treating vascular disease.

2 investors

Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.

2 investors

Tigatx develops engineered IgA antibodies designed to engage neutrophils as a cancer treatment approach. The company focuses on first-in-class immunotherapy for cancer patients.

2 investors

TILT Biotherapeutics develops an investigational adenoviral immunotherapy platform for treating solid tumor cancers, with late-stage development of TILT-123 for head and neck cancer treatment. The company operates as a holding structure with distinct spin-out entities focused on clinical development and preclinical research.

2 investors

Timegate provides real-time process analytics tools for biopharmaceutical manufacturing using patented Timegated Raman Technology, which enables rapid spectral analysis of bioprocesses without fluorescence interference. The company serves biopharmaceutical manufacturers seeking quality control and process monitoring solutions.

2 investors

A venture capital firm that invests in the commercialization of research, with a focus on innovations emerging from the University of Melbourne and its affiliated medical research institutions and hospitals in the Melbourne Biomedical Precinct.

2 investors

TippingPoint Biosciences is a therapeutics company developing a drug discovery platform that targets unstructured regions in chromatin proteins to treat diseases caused by dysfunctional genome chromatin packaging, with a focus on cancer. Its approach aims to increase specificity, reduce toxicity, and limit drug resistance in oncology treatments.

2 investors

Tisento develops pharmaceutical treatments for complex genetic mitochondrial diseases, beginning with MELAS. The company is led by a team of industry veterans focused on improving outcomes for patients with life-altering rare genetic conditions.

2 investors

Tium Bio develops immunotherapy drugs for treating rare and intractable diseases. The company focuses on oncology indications including head and neck cancer, with a pipeline of differentiated candidates in clinical development.

2 investors

TKG develops advanced nucleic acid therapeutics and synthesis technologies for medical applications. The company focuses on applying nucleic acid medicine to address healthcare challenges globally.

2 investors

Tolemy Bio provides a software platform for teams to model, simulate, and optimize biological systems across cell biology, advanced therapeutics, and bioprocessing applications.

2 investors

Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span. Its work includes iPSC-derived thymic organoids and licensed interleukin-7 therapy aimed at improving thymic function and immune resilience.

2 investors

Topos Bio develops an AI-native drug discovery platform focused on intrinsically disordered proteins, which are dynamic proteins associated with diseases such as Alzheimer's and prostate cancer. Its approach models protein ensembles instead of single static structures to target proteins previously considered undruggable.

2 investors

TORL BioTherapeutics develops antibody-drug conjugates (ADCs) targeting Claudin 6 (CLDN6) for the treatment of solid tumors such as ovarian, lung, endometrial, and testicular cancers. Its clinical-stage program centers on ixotatug vedotin, currently in a global Phase 2 study for platinum-resistant ovarian cancer.

2 investors

Toro Bio develops automated systems for cell and gene therapy production at point of care, enabling personalized cancer therapies. The company focuses on streamlining process development and manufacturing for therapeutic applications.

2 investors

TOWING, a startup spun out of Nagoya University, develops and sells "Soratan," a high-functionality biochar made by cultivating soil microbes on biochar derived from local unused biomass, enabling soil preparation in about one month instead of the usual 3–5 years. It provides biochar production support, soil analysis and fertilization planning, and carbon-neutral farming services for sustainable agriculture, with research also aimed at space farming.

2 investors

Tr1X is a biopharmaceutical company developing cell and gene therapies to cure autoimmune and inflammatory diseases with high unmet medical need. The company translates scientific discoveries in immune regulation and regenerative medicine into novel patient therapies.

2 investors

Trace Biosciences develops technology to make nerves visible in real time during surgical procedures, enabling surgeons to better identify and preserve nerve structures. The company targets operating rooms with fluorescent imaging agents and related surgical visualization tools.

2 investors

TrackPaw Scientific develops an automated digital animal tracking system for preclinical drug development laboratories, providing real-time monitoring and data collection to improve animal welfare and research data quality. The platform serves pharmaceutical and biotechnology companies conducting preclinical research.

2 investors

TRACON Pharmaceuticals was a biopharmaceutical company that is currently undergoing liquidation and dissolution as of November 2024.

2 investors

TrakCel develops technology solutions for clinical trial services and cell therapy supply chain management, including cold chain logistics and software platforms for advanced therapy deployment. The company serves pharmaceutical companies and advanced therapy developers managing complex patient-centric operations globally.

2 investors

Transition Bio develops custom chemical additives that stimulate naturally occurring microbes to extract copper from low-grade primary and secondary sulfide ores during heap and dump leaching, improving recovery while reducing acid, water, and energy use. The company targets mining operations seeking to economically process sub-mill grade ore and stockpiles, with plans to extend its bio-optimization approach to other critical minerals.

2 investors

Transposon Therapeutics is a biotechnology company developing therapies for neurodegenerative and aging-related diseases, with a pipeline that includes its lead candidate TPN-101 and novel NRTIs targeting conditions such as PSP, ALS/FTD, and Alzheimer's disease.

2 investors